Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (40,596)	$ (2,255)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	315	34
Research and development expensed - license acquired	3,000	0
Change in fair value of convertible notes payable	109	(2)
Change in fair value of warrant liability	16,132	0
Loss on warrant issuance	5,020	0
Changes in operating assets and liabilities from continuing operations:
Prepaid expenses and other current assets	(890)	(116)
Accounts payable	(371)	1,278
Accrued expenses	517	(170)
Accrued interest	12	113
Licenses payable	2,425	0
Deferred offering costs	140	(66)
Net cash used in operating activities	(14,187)	(1,184)
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants in a private offering	16,520	1,265
Proceeds from issuance of common stock and warrants, pursuant to Securities Purchase Agreement, net of issuance costs	5,930	0
Proceeds from issuance of common stock in at-the-market offering	2,567	0
Proceeds from exercise of warrants	4,443	0
Net cash provided by financing activities	29,460	1,265
Cash flows from discontinued operations:
Net increase in cash	15,273	81
Cash, beginning of period	42	258
Cash, end of period	15,315	339
Supplemental disclosure of cash flow information:
Cash paid for interest	16	0
Cash paid for income taxes	0	0
Non-cash investing and financing activities:
Issuance of common stock for conversion of debt	2,715	0
Issuance of common stock for conversion of accrued interest	164	0
Effect of reverse merger	299	0
Reclass of warrant liabilities related to Series A warrants exercised for cash	5,504	0
Reclass of Series B warrants from warrant liability to stockholders' equity	$ 31,473	$ 0